Detalhe da pesquisa
1.
Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregivers.
CNS Spectr;
28(3): 343-350, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35179458
2.
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.
CNS Spectr;
27(2): 199-207, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33121553
3.
Expert Consensus Statement for Telepsychiatry and Attention Deficit Hyperactivity Disorder.
CNS Spectr;
: 1-34, 2024 May 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38764385
4.
ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines.
Eur Child Adolesc Psychiatry;
33(5): 1605-1608, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38662057
5.
Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregivers - Corrigendum.
CNS Spectr;
28(3): 387, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35791686
6.
Beyond the pill: new medication delivery options for ADHD.
CNS Spectr;
22(6): 463-474, 2017 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28683846
7.
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
CNS Spectr;
21(S1): 45-59, 2016 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28044946
8.
Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Expert Rev Neurother;
24(5): 443-455, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38502148
9.
Are all ADHD medications created equal? Exploring the differences that enable evening dosing.
Postgrad Med;
2024 Jun 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38904469
10.
AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines.
J Am Acad Child Adolesc Psychiatry;
2024 Feb 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38428579
11.
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder.
Transl Psychiatry;
13(1): 228, 2023 06 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37365161
12.
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
Curr Med Res Opin;
39(4): 613-619, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36884024
13.
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
J Clin Psychiatry;
85(1)2023 Dec 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38153320
14.
Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
Front Psychiatry;
13: 824831, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35356713
15.
Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.
Patient Prefer Adherence;
15: 1061-1073, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34054292
16.
WHO Essential Medicines List and methylphenidate for ADHD in children and adolescents - Authors' reply.
Lancet Psychiatry;
11(2): 93-95, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38245024
17.
WHO Model Lists of Essential Medicines: methylphenidate for ADHD in children and adolescents.
Lancet Psychiatry;
10(10): 743-744, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37739581
18.
A clinician's guide to ADHD treatment options.
Postgrad Med;
129(7): 657-666, 2017 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28762862